High‐dose chemotherapy with autologous bone marrow transplantation

Gary Spitzer; Karel Dicke; Axel Rolf Zander; Sundar Jagannath; Lïfda Vellekoop; Emil J. Freireich

doi:10.1002/1097-0142(19840915)54:1+<1216::AID-CNCR2820541320>3.0.CO;2-E

High‐dose chemotherapy with autologous bone marrow transplantation

Gary Spitzer, Karel Dicke, Axel Rolf Zander, Sundar Jagannath, Lïfda Vellekoop, Emil J. Freireich

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

High‐dose chemotherapy using drugs with predominant marrow toxicity and autologous bone marrow support has been investigated in a number of tumor types. High response rates are uniform and complete responses are also high; but long‐term disease‐free survival is occasional. This review discusses those tumor types where patients treated with this approach have survived disease free for several years. Also discussed is what other tumor types and prognostic subgroups of those tumors might benefit therapeutically from high‐dose cytotoxic intensification with autologous bone marrow support or at least have this approach considered as the first alternative for initial relapse.

Original language	English
Pages (from-to)	1216-1225
Number of pages	10
Journal	Cancer
Volume	54
Issue number	1 S
DOIs	https://doi.org/10.1002/1097-0142(19840915)54:1+<1216::AID-CNCR2820541320>3.0.CO;2-E
State	Published - 15 Sep 1984
Externally published	Yes

Access to Document

10.1002/1097-0142(19840915)54:1+<1216::AID-CNCR2820541320>3.0.CO;2-E

Cite this

@article{ac4224edb2ca485db3ac68387a6c16e0,

title = "High‐dose chemotherapy with autologous bone marrow transplantation",

abstract = "High‐dose chemotherapy using drugs with predominant marrow toxicity and autologous bone marrow support has been investigated in a number of tumor types. High response rates are uniform and complete responses are also high; but long‐term disease‐free survival is occasional. This review discusses those tumor types where patients treated with this approach have survived disease free for several years. Also discussed is what other tumor types and prognostic subgroups of those tumors might benefit therapeutically from high‐dose cytotoxic intensification with autologous bone marrow support or at least have this approach considered as the first alternative for initial relapse.",

author = "Gary Spitzer and Karel Dicke and Zander, {Axel Rolf} and Sundar Jagannath and L{\"i}fda Vellekoop and Freireich, {Emil J.}",

year = "1984",

month = sep,

day = "15",

doi = "10.1002/1097-0142(19840915)54:1+<1216::AID-CNCR2820541320>3.0.CO;2-E",

language = "English",

volume = "54",

pages = "1216--1225",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley & Sons Inc.",

number = "1 S",

}

TY - JOUR

T1 - High‐dose chemotherapy with autologous bone marrow transplantation

AU - Spitzer, Gary

AU - Dicke, Karel

AU - Zander, Axel Rolf

AU - Jagannath, Sundar

AU - Vellekoop, Lïfda

AU - Freireich, Emil J.

PY - 1984/9/15

Y1 - 1984/9/15

N2 - High‐dose chemotherapy using drugs with predominant marrow toxicity and autologous bone marrow support has been investigated in a number of tumor types. High response rates are uniform and complete responses are also high; but long‐term disease‐free survival is occasional. This review discusses those tumor types where patients treated with this approach have survived disease free for several years. Also discussed is what other tumor types and prognostic subgroups of those tumors might benefit therapeutically from high‐dose cytotoxic intensification with autologous bone marrow support or at least have this approach considered as the first alternative for initial relapse.

AB - High‐dose chemotherapy using drugs with predominant marrow toxicity and autologous bone marrow support has been investigated in a number of tumor types. High response rates are uniform and complete responses are also high; but long‐term disease‐free survival is occasional. This review discusses those tumor types where patients treated with this approach have survived disease free for several years. Also discussed is what other tumor types and prognostic subgroups of those tumors might benefit therapeutically from high‐dose cytotoxic intensification with autologous bone marrow support or at least have this approach considered as the first alternative for initial relapse.

UR - http://www.scopus.com/inward/record.url?scp=0021215172&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19840915)54:1+<1216::AID-CNCR2820541320>3.0.CO;2-E

DO - 10.1002/1097-0142(19840915)54:1+<1216::AID-CNCR2820541320>3.0.CO;2-E

M3 - Article

C2 - 6088021

AN - SCOPUS:0021215172

SN - 0008-543X

VL - 54

SP - 1216

EP - 1225

JO - Cancer

JF - Cancer

IS - 1 S

ER -

High‐dose chemotherapy with autologous bone marrow transplantation

Abstract

Access to Document

Fingerprint

Cite this